Montosun Biopharma

Montosun Biopharma is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative treatments for metabolic and inflammatory diseases. The company's lead program, MT-101, is a potent xanthine oxidase inhibitor currently in Phase 3 clinical trials for the treatment of hyperuricemia and gout. Montosun focuses on addressing unmet medical needs in the management of uric acid levels, aiming to provide safer and more effective alternatives to existing therapies. Their research and development efforts are primarily centered on small molecule drug discovery and clinical advancement within the Chinese market.